Assess whether a CMC change is a comparability or a new product (b13e69)

Situation

In a rare-disease team designing a pediatric plan, 505(b)(2) literature-to-product bridge table is the evidence after a boxed-warning proposal from the review division. Regulatory-affairs lead has to pick A CMC change is a comparability or A new product for this Pharma & Life Sciences Pharmacovigilance close using 505(b)(2) literature-to-product bridge table.

Decision

Regulatory-affairs lead in a rare-disease team designing a pediatric plan must choose A CMC change is a comparability / A new product using 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division.

Hypotheses to test

• Regulatory-affairs lead can defend A CMC change is a comparability from 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division in a Pharma & Life Sciences challenge.
• Regulatory-affairs lead cannot defend A CMC change is a comparability from 505(b)(2) literature-to-product bridge table; A new product is what the extract actually supports after a boxed-warning proposal from the review division.
• A boxed-warning proposal from the review division never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close a CMC change is.
• Two facts in 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division conflict for regulatory-affairs lead; hold this Pharmacovigilance file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMC change is.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim regulatory-affairs lead would keep.
• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a boxed-warning proposal from the review division and write the one fact that would move a CMC change is for regulatory-affairs lead.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for regulatory-affairs lead in a rare-disease team designing a pediatric plan.